Comparative Pharmacology
Head-to-head clinical analysis: BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE versus PROMETHAZINE DM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE versus PROMETHAZINE DM.
BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE vs PROMETHAZINE DM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bromodiphenhydramine hydrochloride is a first-generation antihistamine that antagonizes histamine H1 receptors, reducing allergic symptoms. Codeine phosphate is an opioid agonist at mu-opioid receptors, producing analgesia and antitussive effects. Combination provides enhanced cough suppression.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, antiemetic via blockade of dopamine D2 receptors in the chemoreceptor trigger zone, and sedative via central anticholinergic effects. Dextromethorphan is an NMDA receptor antagonist and sigma-1 receptor agonist, suppressing cough by central action on the cough center.
5 mL of oral solution (containing bromodiphenhydramine hydrochloride 12.5 mg and codeine phosphate 10 mg) every 4-6 hours as needed; maximum 4 doses in 24 hours.
2 teaspoonfuls (10 mL) orally every 4-6 hours, not to exceed 8 teaspoonfuls (40 mL) per 24 hours.
None Documented
None Documented
Codeine: 2.5-3.5 h (adults), prolonged in hepatic impairment. Diphenhydramine: 4-8 h (adults), extended in elderly.
16-19 hours (terminal); note: effect may last longer due to active metabolites and tissue binding
Renal: 70-80% as metabolites (codeine ~10% unchanged; diphenhydramine <5% unchanged). Biliary/fecal: 20-30%.
Renal (70-80% as metabolites, <1% unchanged); biliary/fecal (20-30%)
Category A/B
Category A/B
Antihistamine
Antihistamine / Antiemetic